Regulatory approval for new isotope production at Bruce

Canada's Bruce Power has received approval from the Canadian Nuclear Safety Commission for the commercial production of the medical radioisotope lutetium-177 in its nuclear power plants. The project to produce the innovative therapeutic isotope, which is used in the treatment of prostate cancer and neuroendocrine tumours, is a partnership between more